Biotech Stocks Reviews
- Bellus Uplists & Fennec’s Plan B for Self-Commercialization
Sat, Sep 14
Last week Bellus uplisted to the Nasdaq, trading under ticker BLU. To complete the uplisting, Bellus · more » - Adverum’s Phase 1 Disappoints on Visual Acuity & Inflammation
Thu, Sep 12
Adverum released preliminary Phase 1 data prior to the market opening. Data was rather vague and did · more » - Market Overreacts to Amarin’s 3 Month Delay
Fri, Aug 9
What Happened?Amarin (AMRN) was down 20% in aftermarket trading yesterday upon announcing that the FDA · more » - Expectations for Adverum’s WetAMD Phase 1 Data in September
Sun, Jul 28
ADVM will present Phase 1 data in Wet AMD this September We set expectations for September data by · more » - Key Takeaways From Bellus’ Chronic Cough KOL Call
Tue, Jul 16
Bellus hosted their Chronic Cough KOL meeting this morning. It was paneled by: Jacky Smith: lead · more » - Merck’s Plan of a P2X3 Pipeline Lifts Bellus
Sat, Jun 22
Last week, Bellus (BLUSF) rallied from $1.50 range to over $2.00, touching a high of $2.31. This all · more » - Late 2019 Data Could Position Gene Therapy Company As Leading Candidate in Wet AMD
Mon, Jun 3
Adverum (ADVM) has rallied year to date from $3.50 to $10/share as the market is picking up on the gene · more » - Acer’s Clinically Relevant Data Could Be Enough For Desperate Patient Population
Thu, May 2
Acer Therapeutics (ACER) has a PDUFA date on June 25, 2019 for the treatment of vascular Ehlers-Danlos · more » - With Completion of Spring Bank’s (SBPH) ACHIEVE, All Eyes on Gilead’s Combination Data
Fri, Apr 12
Spring Bank (SBPH) presented data for their Phase 2 ACHIEVE trial at EASL conference today, including · more »